Back to News >

FUJIFILM Diosynth Biotechnologies (FDB), a world leading cGMP Contract Development and Manufacturing Organization (CDMO) supporting its partners in the biopharmaceutical industry with the development and production of their biologics, vaccines and gene therapies, held a ground breaking ceremony on March 12, 2020 signalling commencement of construction of the company’s new BioCampus at its Billingham, UK location.

This BioCampus development will include the construction of 42,000 square foot purpose built office accommodation and visitor centre in addition to making ready the land for potential expansion that could include additional research and development laboratories and new manufacturing facilities.

Paul Found, chief operating officer, FUJIFILM Diosynth Biotechnologies, United Kingdom said: 

“This will enable us to significantly enhance the quality of the working environment for our existing employees and provide visitors with a fantastic arrival experience,”

The up to £14.5M development is partly supported by the Tees Valley Mayor and Combined Authority (TVCA) through grant funding.

It is expected that the new office accommodation will house approximately 250 of FDB’s existing staff and support the addition of further 50 positions at the company’s UK location to support its growing portfolio of partner programs.

Tees Valley Mayor Ben Houchen said:

“FUJIFILM Diosynth Biotechnologies is doing fantastic work in our hugely important bioscience sector and creating the skilled jobs we need. Our funding for this new development recognises its commitment to the region and the opportunities it is providing for local people,”

”By backing FUJIFILM Diosynth Biotechnologies and other organisations such as Teesside University’s centre for excellence and the National Horizons Centre, the Tees Valley is making its mark as a sector leader, driving forward innovation and jobs.”

Simon Clarke MP, Minister of State, Ministry of Housing, Communities and Local Government said: 

“We are committed to levelling up across the Northern Powerhouse and ensuring every community has the support and investment it needs to flourish,”

“This world-class research centre right in the heart of the Tees Valley – backed with £2.65 million from the Government’s Local Growth Fund – will be at the forefront of medical innovation as well as creating jobs and attracting further investment.

It builds on almost £5 million of Local Growth Fund already spent in Stockton North and the further investment in the area through the Future High Streets Fund.”

The construction is expected to be completed by March 2021.

Credit: FUJIFILM Diosynth Biotechnologies